Speaker(s): 

Dominick Patafio, PharmD, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Compare clotting factor replacement products approved in hemophilia von Willebrand Disease
• Describe the pharmacokinetic and pharmacodynamic factors that affect response
• Discuss inhibitors and their impact on clotting factor concentrate administration
• Determine a process for monitoring clotting factor levels during clotting factor replacement
• Examine the clinical data surrounding clotting factor prophylaxis
• Describe the guideline recommendations surrounding clotting factor replacement in acute bleeds, surgery, and pregnancy

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, EdD, BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH and Lisabeth Karetsky, CPhT have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None